Search our science

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d’Oiron R, Benchikh El Fegoun S, Kessler C. Delphi expert consensus statements on clinical evaluation of bleeds in patients with acquired haemophilia. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Carcao M, Kearney S, Taki M, Rubens D, Pietzko K, Santagostino E. Nonacog beta pegol administered for at least 5 years shows long-term safety and efficacy in previously treated children with haemophilia B. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Sun J, Xu W, Wu R, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Korsholm L, Matytsina I, Zhang S, Yang R. Successful haemostatic response and effective prophylaxis with turoctocog alfa in previously treated patients from China with severe haemophilia A (guardian 7). Research and Practice in Thrombosis and Haemostasis. 2019;3(Suppl. 1):265.

Gupta N, Benbouzid A, Belhani M, El Andaloussi M, Maani K, Wali Y, Benchikh El Fegoun S, Ali Saad H, Mahlangu J. HAEMOcare: The first international epidemiological study measuring burden of hemophilia in developing countries. TH Open. 2019;03(02):e190-e199.

Tiede A,Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d’Oiron R, Benchikh El Fegoun S, Kessler C. Delphi expert consensus statements on clinical evaluation of bleeds in patients with acquired haemophilia. Res Pract Thromb Haemost . 2019;3(Suppl 1):1-891.

Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P. Immunogenicity, safety, pharmacokinetics and preliminary efficacy results from the first human subcutaneous factor VIII trial (subcutaneous turoctocog alfa pegol, SC N8-GP) in previously treated patients with hemophilia A (alleviate 1). Res Pract Thromb Haemost. 2019;3(Suppl. 1):1-228.

Carcao M, Kearney S, Taki M, Rubens D, Pietzko K, Santagostino E. Long-term safety and efficacy of nonacog beta pegol in previously treated children with haemophilia B, treated for at least 5 years. Res Pract Thromb Haemost. 2019;3(Suppl 1):1-891.

de Moerloose P, Davis J, Benchikh El Fegoun S, Habis R, Klamroth R. Barriers and challenges for the fast treatment of bleeds in the non-hemophilia treatment center hospital setting. Res Pract Thromb Haemost . 2019;3(Suppl 1):1-891.

Sun J, Xu W, Wu R, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Yang R. Successful haemostatic response during the treatment of bleeding episodes and effective prophylaxis with turoctocog alfa in previously treated patients from China with severe haemophilia A (guardian 7). Research and Practice in Thrombosis and Haemostasis. 2019;3(Supplement 1):265-266.

Chowdary P, Chitlur M, Clausen WHO, Escobar M, Kearney S, Landorph A, Hvitfeldt Poulsen L, Santagostino E. N8-GP treatment sustains low bleeding rates in patients with severe haemophilia A. Res Pract Thromb Haemost. 2019;3(Suppl 1):1-891.

Curry NJ, Chowdary P, Clausen WHO, Landorph A, Lentz SR, Meunier S, Oldenburg J, Rageliene L, Santagostino E. Long-term safety of N8-GP (turoctocog alfa pegol) prophylaxis in patients with severe haemophilia A. Res Pract Thromb Haemost. 2019;3(Suppl 1):1-891.

Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY,. Real-world utilities and health-related quality of life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adherence. 2019;13:941-957.

Curry N, Albayrak C, Escobar M, Holme PA, Kearney S, Klamroth R, Misgav M, Negrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz S. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia. 2019;25(3):373-381.

Lorenzato C, Bonamichi-Santos R, Fagundes GZZ, Ozelo MC. Haemophilia Experiences, Results and Opportunities (HERO study) in Brazil: Assessment of the psychosocial effects of haemophilia in patients and caregivers. Haemophilia. 2019;00:1-11.

Wang M, Chrisentery-Singleton T, Tarantino MD, Saad H, Kreilgaard M. Modeling of daily Turoctocog Alfa (rFVIII) Administrations for Active Patients with Hemophilia A. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Wang M, Chrisentery-Singleton T, Tarantino MD, Saad H, Kreilgaard M. Modeling of Daily Turoctocog Alfa (rFVIII) Administrations for Active Patients with Hemophilia A. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Croteau S, Cutter S, Hernandez G, Wicklund B, Dreyer Gillette M, Haugstad K, Cooper D, Ostrow V, Nadglowski J. Awareness, Care, and Treatment in Obesity Management to inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of United States (US) Patients with Hemophilia and Obesity (PwHO) and their Partners and Caregivers. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Wang M, Peltier S, Baumann K, Sidonio R, Wadden T, Witkop M, Cooper D, Waters E, Kahan S. Awareness, Care, and Treatment in Obesity Management to inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of United States (US) Hemophilia Treatment Center (HTC) Professionals. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Wheeler A, Lentz S, Kearney S, Yee D, Cooper D, Escobar M. Turoctocog alfa pegol provides reliable prolongation in half-life compared with prior FVIII product: Pharmacokinetic analysis of pathfinder1 and pathfinder5. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Wheeler A, Lentz S, Kearney S, Yee D, Moss J, Cooper D, Escobar M. Turoctocog alfa pegol (N8-GP) provides reliable prolongation in half-life compared with prior FVIII product: PK analysis of pathfinder1 and pathfinder5. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Hampton K, Chowdary P, Escobar M, Clausen WHO, Landorph A, Santagostino E. Efficacy and safety of turoctocog alfa pegol during orthopaedic surgery in patients with severe haemophilia A. World Federation of Hemophilia - 16th International Musculoskeletal Congress. 2019.

Croteau S, Cutter S, Hernandez G, Wicklund B, Dreyer Gillette M, Haugstad K, Cooper D, Ostrow V, Nadglowski J. Awareness, Care, and Treatment in Obesity Management to Inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): A Survey of US Patients with Hemophilia and Obesity and their Partners and Caregivers. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Wang M, Peltier S, Baumann K, Sidonio R, Witkop M, Cooper D, Waters E, Kahan S. Awareness, Care, and Treatment in Obesity Management to Inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a Survey of United States Hemophilia Treatment Center Professionals. Hemostasis & Thrombosis Research Society - 2019 Scientific Symposium. 2019.

Hampton K, Chowdary P, Escobar M, Clausen WHO, Landorph A, Santagostino E. Efficacy and safety of turoctocog alfa pegol during orthopaedic surgery in patients with severe haemophilia A. World Federation of Hemophilia - 16th International Musculoskeletal Congress. 2019.

Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H and Oldenburg J. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII. Patient Prefer Adherence. 2019;2019(13):497-513.

Rexen P, Taaftegaard Jensen J, Bjørn Schwerin N, Kozina E. Stability of eptacog alfa (activated) in automated infusion pump. TH Open. 2019;3:e45-e49.

Escuriola-Ettingshausen C, Hegemann I, Simpson M, Cuker A, Kulkarni R, Pruthi R, Garly M-L, Meldgaard RM, Persson P, Klamroth R. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial. Res Pract Thromb Haemost. 2019;3:268-276.

Casas Patarroyo CP, del Pilar Agudelo López C, Galvez K, Ibarra JL, Rojas SM, Bernal LI. Importancia de la orientación diagnóstica en hemofilia A adquirida (Adequate diagnosis of acquired hemophilia A). Rev Med Chil. 2019;147(3): 334-341.